Capivasertib
Capivasertib is an investigational drug that functions as a selective inhibitor of the AKT (protein kinase B) pathway. It is being studied for its potential use in the treatment of various types of cancer.
Mechanism of Action[edit]
Capivasertib targets and inhibits the activity of the AKT enzyme, which plays a crucial role in the PI3K/AKT/mTOR pathway. This pathway is involved in cell growth, proliferation, and survival. By inhibiting AKT, Capivasertib can potentially reduce tumor growth and induce apoptosis in cancer cells.
Clinical Development[edit]
Capivasertib is currently undergoing clinical trials to evaluate its efficacy and safety in treating different types of cancer, including breast cancer, prostate cancer, and lung cancer. These trials are designed to determine the optimal dosing, potential side effects, and overall effectiveness of the drug.
Potential Indications[edit]
Capivasertib is being investigated for use in several types of cancer, particularly those that exhibit aberrant activation of the PI3K/AKT/mTOR pathway. Some of the cancers under investigation include:
Side Effects[edit]
As with many investigational drugs, Capivasertib may cause a range of side effects. Commonly reported side effects in clinical trials include:
Research and Future Directions[edit]
Ongoing research aims to better understand the full potential of Capivasertib in cancer therapy. This includes exploring its use in combination with other treatments, such as chemotherapy, radiation therapy, and other targeted therapies. Researchers are also investigating biomarkers that may predict which patients are most likely to benefit from Capivasertib treatment.
See Also[edit]
References[edit]
External Links[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
